Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Authors' conclusion
In our pilot study of ICU patients with type 2 diabetes, empagliflozin therapy was associated with increases in sodium and chloride levels but was not significantly associated with acid-base changes, hypoglycemia, ketoacidosis, worsening kidney function, bacteriuria, or mortality.
Study context
- Population
- ICU patients with type 2 diabetesmatched
- Participants
- 18 vs 72
- Comparison
- Treatment vs Control
- Treatmentn = 18
- Controln = 72reference
- Outcome
- Maximum increase in sodium and chloride levels
Methodological detailsmatched (age, HbA1c, ICU duration)
- Matched (age, HbA1c, ICU duration)
Main finding
As reported in the abstract
| Group | Value | Chloride, median (IQR) |
|---|---|---|
| Control | median 3 (IQR 1–10) mmol/l | 3 (2-8) mmol/l |
| Treatment | median 9 (IQR 3–12) mmol/l | 8 (3-10) mmol/l |
Value
Controlmedian 3 (IQR 1–10) mmol/l
Treatmentmedian 9 (IQR 3–12) mmol/l
Chloride, median (IQR)
Control3 (2-8) mmol/l
Treatment8 (3-10) mmol/l
- Treatment vs Control: P = 0.045 — sodium
- Treatment vs Control: P = 0.059 — chloride
Observational data: associations, not effects.
Further findings
Hospital mortality
P = 0.79
Strong ion difference, pH, base excess
- No differences
Safety
Hypoglycemia
Worsening kidney function
P = 0.54
Positive urine cultures
P = 0.28
Events
| Outcome | Treatment | Control |
|---|---|---|
| Ketoacidosis | 0 | 1 |
Original publication
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study. Crit Care. Published 16 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →